Business
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary LeadsBody platform, fo
About this update from Nanjing Leads Biolabs Co., Ltd. Class H
[{"type":"text","content":"NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary LeadsBody platform, for the treatment of relapsed/refractory multiple myeloma (RRMM).","length":638,"tagName":"p"},{"type":"text","content":"The study, led by Professor Jin Lu of Peking University People's Hospital and conducted across 17 centers in China, demonstrated that LBL-034 achieved favorable safety and highly encouraging anti-tumor activity, including in high-risk refractory subgroups, highlighting its potential as a best-in-class therapeutic candidate.","length":329,"tagName":"p"},{"type":"text","content":"The key clinical highlights of LBL-034","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Safe escalation to 1200 μg/kg with no DLTs or MTD reached.Adverse events impacting quality of life were predominantly Grade 1–2 and occurred mainly during Cycle 1, with markedly lower incidence thereafter. Taste, skin, and nail toxicities were infrequent and generally self-resolving.","length":290,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong efficacy across dose levels 400–1200 μg/kg (n=40).ORR reached 82.5%, with ≥CR at 52.5%, ≥VGPR at 72.5%, and MRD negativity at 80.0%.At 800 μg/kg, ORR and ≥CR were 90.9% and 63.6%, respectively.","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Robust activity in difficult-to-treat RRMM subgroups.","length":58,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Extramedullary disease (EMD): ORR 75.0%, including two sCRs. At 1200 μg/kg, ORR in EMD patients reached 100%, with rapid EMD lesion regression observed.","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Prior BCMA-treated patients: ORR 85.7%, with CR/sCR 57.1%.","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":220,"olType":false}]},{"val":[{"t...